about
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgeryRestricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer.Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancerSelf-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyHuman papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study.The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.Poor efficacy of BEP polychemotherapy in metastatic spermatocytic seminoma.PET/MR in prostate cancer: technical aspects and potential diagnostic value.CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancerImaging for Prostate Cancer Recurrence.Current use of PSMA-PET in prostate cancer management.Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumour Burden in Prostate Cancer using (68)Ga-PSMA-PET/CT.Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer.Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin.(68)Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy.Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.Multimodal image-guided prostate fusion biopsy based on automatic deformable registration.[Inguinal lymphadenectomy in penile cancer: Study for prevention of wound complications after inguinal lymphadenectomy in patients with penile cancer by epidermal vacuum therapy (PräVAC, EUDAMED: CIV-12-07-008204; DRKS-ID: DRKS00005257)].Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.Correlation of tumor-associated macrophages and NK cells with bladder cancer size and T stage in patients with solitary low-grade urothelial carcinoma.Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis.Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET.Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival.Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome.The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.PSMA-targeted imaging of prostate cancer: evolution of a success story.PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer.
P50
Q26747480-BBB805BD-FBF5-43B4-B780-165061655A87Q30396825-D9FE7454-5DA9-4F38-96F3-5BD7376CC6BAQ33583831-92BE4DA5-E888-4728-A236-11DE2CAD9A7FQ33670900-38E7E545-4AB1-4D59-A7A6-6D564F71BEE1Q35746834-1C49B6A3-BABA-433A-9607-7E9B3FC0D12DQ36076820-7779C0A0-5DD0-417C-99FD-357822974B12Q36491446-6F621A55-6FC2-49A4-BE31-F3771959F21AQ36942136-44374AA0-125E-4A4C-B2C5-D9A9FAE62CD4Q37810504-EA4DF43C-EDD8-4D61-BBB9-BD3B1B09F666Q38109083-C4C2881C-9EA3-41DE-A981-8540CB9EBE97Q38363358-0F5CB3F4-5C64-466F-ABB4-0C99AE4B6FB2Q38597244-518E30AF-ACF4-45D2-B954-7F9A1EB383D2Q38599748-25CC093C-4A84-4964-8A03-A762410C1A4AQ38655167-48C22374-C903-4F94-A3D4-A8CE0BDC0D90Q38744524-86A93C61-5575-4EE1-AC6B-AE9401C0DD43Q38762861-9B4C927B-FED0-43AE-893B-3D46D805E373Q38853977-08A55620-4D86-4A66-A4CD-3433785EAB10Q38895102-EE14A7C7-8C3C-4C5D-B69F-696AFFFCD415Q39009150-B08C993E-1A48-472B-B968-65A0CACC15A4Q39383062-A98FA3CE-3485-4537-B040-54A3EF3912D6Q39690658-C93CAB85-7A71-4C80-89A1-C9322A66E9D2Q39930921-6B72610F-92F5-4E00-9F6D-6F8DDCA123CFQ40214122-75872883-8C71-4547-AB67-2ADC0DB14783Q40243006-98F57030-7AA3-4E7B-9F4B-4AFA8DFC16C3Q40331189-ECC8CC7E-76E0-44B4-98F2-DCEB857CA148Q40379924-761E98C1-F0D9-4884-AA42-E17949DA3E3AQ40468376-B1FEF747-13CD-4676-9D11-8417C4B660D0Q40857650-C34F403B-6BEF-4700-BFC1-772EF8AE7BB5Q40904766-C1747042-E33E-4D61-8F6D-66D43F2DC8F0Q40959799-B06491CA-8002-40EC-B992-1F251AEA3DA1Q41038146-986FFA8C-C874-479C-A47E-04C93A2E4DDAQ41056298-C2B9BB50-AE9F-4FF9-9104-A63268E6281EQ41288218-B8B01E2B-BFD4-441C-88B5-D6E966959071Q41354108-1376CA3C-E107-4BC3-86E6-F6FA721B2137Q41496553-6B0ECC83-0BBA-4E46-B3EF-28FBE8C670C9Q41649301-D3D63EDA-F8B5-4A94-B652-718DD7F71CB0Q41685417-71D4F4D6-824A-4765-AE7D-DA513B9BB9ABQ42075561-ED109285-0AE6-4224-8029-8241C26190B4Q42335927-5F9D2365-3B4A-4DCC-ADA4-DF9BD5473FDDQ42371661-39F0A3B9-9E46-45F7-8D3B-9D19EF07AB49
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Tobias Maurer
@ast
Tobias Maurer
@en
Tobias Maurer
@es
Tobias Maurer
@nl
Tobias Maurer
@sl
type
label
Tobias Maurer
@ast
Tobias Maurer
@en
Tobias Maurer
@es
Tobias Maurer
@nl
Tobias Maurer
@sl
prefLabel
Tobias Maurer
@ast
Tobias Maurer
@en
Tobias Maurer
@es
Tobias Maurer
@nl
Tobias Maurer
@sl
P214
P1053
R-7561-2017
P106
P108
P1153
7005701751
P21
P214
P31
P3829
P496
0000-0002-5660-7691
P734
P735
P7859
viaf-77407776